From Clinical Analytics Platform TriNetX Raises $40M to Speed Drug Trials:

Gadi Lachman, TriNetX CEO

Gadi Lachman, TriNetX CEO—

Courtesy photo

Underwriters and Partners

Xconomy Insight

Sponsored · Video
The Importance of Early Planning for Biotechs & Engaging with a CRO for Molecule Development
A Fireside Chat with Medpace's Regulatory Affairs Director David Horton
Medpace

Sponsored · Whitepaper
Navigating Challenges & Advancing Clinical Development: A Toolkit for Emerging Biotechs
How incorporating more virtual/hybrid trials and decentralized research into clinical development can better integrate healthcare into patients’ real lives and accelerate approval of new medications.
Medpace

Sponsored · Whitepaper
The Importance of Early Key Opinion Leader Outreach in the Biologics & Biosimilars Marketplace
Acknowledging various stakeholder networks and regulatory environment variances is essential to uncover the right decision-makers in support of biologics or biosimilars
IBM Watson

Xconomy on Demand

We offer a number of ways to subscribe for free!